Skip to main content
SpringerLink
Log in

Medication-Assisted Treatment (MAT) 1: Opioid Substitution Therapy

  • Chapter
  • First Online:
Opioids

Abstract

This chapter is the first of two parts describing the advantages, standards, and goals of medication-assisted treatment (MAT) for opioid use disorders. MAT is a complex biopsychosocial intervention with the provision of opioid substitution treatment (OST) at its core. These chapters aim to provide the clinician with charts, tables, and clinical guidance around the prescribing of OST within MAT. This first part (this chapter) covers the assessment of patients with opioid use disorders (OUDs), initiation, titration, and maintenance with OST, as well as physical monitoring and the treatment of those with OUDs requiring admission to hospital.

Data presented here is based on clinical guidelines and the experience in treating persons with OUDs in Scotland, United Kingdom (UK), and reflects evolution in practice in response to the high levels of drug deaths and Scottish national MAT standards published in May 2021. Within the UK, the National Health Service (NHS) exists as a single-payer healthcare system, providing universal care to all residents. This of course is not the case worldwide, and there is substantial variation in availability of services between countries. Clinicians should always ensure that they are familiar with what services are available locally as well as local licensing and legal requirements around prescribing OST, as substitute medications are usually controlled drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Maglione MA, Raaen L, Chen C, Azhar GS, Nima S, Shen M, et al. Effects of Medication-Assisted Treatment (MAT) for opioid use disorder on functional outcomes: a systematic review. Rand Health Q. 2020;8(4):RR-2108-OSD.

    PubMed  PubMed Central  Google Scholar 

  2. Sanger N, Shahid H, Dennis BB, Hudson J, Marsh D, Sanger S, et al. Identifying patient-important outcomes in medication-assisted treatment for opioid use disorder patients: a systematic review protocol. BMJ Open [Internet]. 2018;8(12):e025059. Available from: http://bmjopen.bmj.com/content/8/12/e025059.

    Article  Google Scholar 

  3. Independent Expert Working Group. Clinical guidelines on drug misuse and dependence update. Global and Public Health/Population Health/Healthy Behaviours/25460; 2017.

    Google Scholar 

  4. Ma J, Bao Y-P, Wang R-J, Su M-F, Liu M-X, Li J-Q, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2019;24(12):1868–83.

    Article  PubMed  Google Scholar 

  5. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–6.

    Article  PubMed  Google Scholar 

  6. Scottish Government. Medication Assisted Treatment (MAT) standards for Scotland access, choice, support [Internet]. 2021 [cited 2021 Sept 12]. Available from: https://www.gov.scot/binaries/content/documents/govscot/publications/independent-report/2021/05/medication-assisted-treatment-mat-standards-scotland-access-choice-support/documents/medication-assisted-treatment-mat-standards-scotland-access-choice-support/medication-assisted-treatment-mat-standards-scotland-access-choice-support/govscot%3Adocument/medication-assisted-treatment-mat-standards-scotland-access-choice-support.pdf.

  7. Kourounis G, Richards BDW, Kyprianou E, Symeonidou E, Malliori M-M, Samartzis L. Opioid substitution therapy: lowering the treatment thresholds. Drug Alcohol Depend. 2016;161:1–8.

    Article  PubMed  Google Scholar 

  8. GOV.UK. Drug misuse and dependence: UK guidelines on clinical management [Internet]. [cited 2021 Jun 21]. Available from: https://www.gov.uk/government/publications/drug-misuse-and-dependence-uk-guidelines-on-clinical-management.

  9. GOV.SCOT. Medication Assisted Treatment (MAT) standards: access, choice, support [Internet]. [cited 2021 Jul 24]. Available from: https://www.gov.scot/publications/medication-assisted-treatment-mat-standards-scotland-access-choice-support/.

  10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders [Internet]. 5th ed. American Psychiatric Association; 2013 [cited 2021 Jul 24]. Available from: http://psychiatryonline.org/doi/book/10.1176/appi.books.9780890425596.

  11. Herget G. Methadone and buprenorphine added to the WHO list of essential medicines. HIVAIDS Policy Law Rev. 2005;10(3):23–4.

    Google Scholar 

  12. Harm Reduction International. The global state of harm reduction: 6th edition [Internet]. 2018 [cited 2021 Sept 12]. Available from: https://www.hri.global/files/2019/02/05/global-state-harm-reduction-2018.pdf.

  13. Joint United Nations Programme on HIV/AIDS. Do no harm: health, human rights and people who use drugs. UNAIDS; 2016.

    Google Scholar 

  14. MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945.

    Article  PubMed  PubMed Central  Google Scholar 

  15. NICE. Overview | Methadone and buprenorphine for the management of opioid dependence | Guidance | NICE [Internet]. [cited 2021 Jun 21]. Available from: https://www.nice.org.uk/guidance/ta114.

  16. NICE. BNF: British National Formulary – NICE [Internet]. [cited 2021 Jun 21]. Available from: https://bnf.nice.org.uk/treatment-summary/substance-dependence.html.

  17. Center for Substance Abuse Treatment (US); Knowledge Application Program (US). Medications for opioid use disorder: for healthcare and addiction professionals, policymakers, patients, and families (SAMHSA/CSAT treatment improvement protocols) [Internet]. Rockville: Substance Abuse and Mental Health Services Administration (US); 2018 [cited 2021 Jul 26]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK535268/.

  18. Kristensen K, Christensen CB, Christrup LL. The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci. 1995;56(2):PL45–50.

    Article  PubMed  Google Scholar 

  19. Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med. 2000;67(5–6):347–64.

    CAS  PubMed  Google Scholar 

  20. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153–93.

    Article  CAS  PubMed  Google Scholar 

  21. Wolff K, Rostami-Hodjegan A, Hay AW, Raistrick D, Tucker G. Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction. 2000;95(12):1771–83.

    Article  CAS  PubMed  Google Scholar 

  22. Chugh SS, Socoteanu C, Reinier K, Waltz J, Jui J, Gunson K. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med. 2008;121(1):66–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Lutfy K, Cowan A. Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol. 2004;2(4):395–402.

    Article  CAS  PubMed  Google Scholar 

  24. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003;70(2, Supplement):S13–27.

    Article  CAS  PubMed  Google Scholar 

  25. Schottenfeld RS, Pakes J, O’Connor P, Chawarski M, Oliveto A, Kosten TR. Thrice-weekly versus daily buprenorphine maintenance. Biol Psychiatry. 2000;47(12):1072–9.

    Article  CAS  PubMed  Google Scholar 

  26. Paone D, Tuazon E, Stajic M, Sampson B, Allen B, Mantha S, et al. Buprenorphine infrequently found in fatal overdose in New York City. Drug Alcohol Depend. 2015;155:298–301.

    Article  CAS  PubMed  Google Scholar 

  27. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35(2):253–9.

    Article  PubMed  Google Scholar 

  28. NHS Fife – Methadone tolerance testing procedure (2011) [Internet]. [cited 2021 Aug 31]. Available from: https://www.fifeadtc.scot.nhs.uk/media/7032/a1-procedure-for-tolerance-testing-final-april-2011.pdf.

  29. Buprenorphine | Prescribing information | Opioid dependence | CKS | NICE [Internet]. [cited 2021 Jun 27]. Available from: https://cks.nice.org.uk/topics/opioid-dependence/prescribing-information/buprenorphine/.

  30. Tay Wee Teck J, Baldacchino A, Gibson L, Lafferty C. Using microdosing to induct patients into a long-acting injectable buprenorphine depot medication in low threshold community settings: a case study. Front Pharmacol. 2021;12:294.

    Article  Google Scholar 

  31. Chappuy M, Trojak B, Nubukpo P, Bachellier J, Bendimerad P, Brousse G, et al. Prolonged-release buprenorphine formulations: perspectives for clinical practice. Therapie. 2020;75(5):397–406.

    Article  PubMed  Google Scholar 

  32. Parsons G, Ragbir C, D’Agnone O, Gibbs A, Littlewood R, Hard B. Patient-reported outcomes, experiences and satisfaction with weekly and monthly injectable prolonged-release buprenorphine. Subst Abus Rehabil. 2020;11:41–7.

    Article  Google Scholar 

  33. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev [Internet]. 2014;(2):CD002207. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002207.pub4/full.

  34. Roux P, Lions C, Michel L, Cohen J, Mora M, Marcellin F, et al. Predictors of non-adherence to methadone maintenance treatment in opioiddependent individuals: implications for clinicians. Curr Pharm Des. 2014;20(25):4097–105.

    Article  CAS  PubMed  Google Scholar 

  35. Bao Y-P, Liu Z-M, Epstein DH, Du C, Shi J, Lu L. A meta-analysis of retention in methadone maintenance by dose and dosing strategy. Am J Drug Alcohol Abuse. 2009;35(1):28–33.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Amass L, Bickel WK, Crean JP, Blake J, Higgins ST. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology. 1998;136(3):217–25.

    Article  CAS  PubMed  Google Scholar 

  37. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend. 1995;40(1):27–35.

    Article  CAS  PubMed  Google Scholar 

  38. Pani PP, Trogu E, Maremmani I, Pacini M. QTc interval screening for cardiac risk in methadone treatment of opioid dependence. Cochrane Database Syst Rev. 2013;(6):CD008939.

    Google Scholar 

  39. Lofwall MR, Stitzer ML, Bigelow GE, Strain EC. Comparative safety and side effect profiles of buprenorphine and methadone in the outpatient treatment of opioid dependence. Addict Disord Their Treat. 2005;4(2):49–64.

    Article  Google Scholar 

  40. Bruce RD, Altice FL. Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases. Am J Drug Alcohol Abuse. 2007;33(6):869–74.

    Article  PubMed  Google Scholar 

  41. Ostgathe C, Voltz R, Van Aaaken A, Klein C, Sabatowski R, Nauck F, et al. Practicability, safety, and efficacy of a “German model” for opioid conversion to oral levo-methadone. Support Care Cancer. 2012;20(9):2105–10.

    Article  PubMed  Google Scholar 

  42. Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: the international experience. Clin Infect Dis. 2006;43(Supplement_4):S197–215.

    Article  CAS  PubMed  Google Scholar 

  43. Strang J, Reed K, Bogdanowicz K, Bell J, van der Waal R, Keen J, et al. Randomised comparison of a novel buprenorphine oral lyophilisate versus existing buprenorphine sublingual tablets in opioid-dependent patients: a first-in-patient phase II randomised open label safety study. Eur Addict Res. 2017;23(2):61–70.

    Article  PubMed  Google Scholar 

  44. Orman JS, Keating GM. Buprenorphine/naloxone. Drugs. 2009;69(5):577–607.

    Article  CAS  PubMed  Google Scholar 

  45. Lofwall MR, Walsh SL, Nunes EV, Bailey GL, Sigmon SC, Kampman KM, et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med. 2018;178(6):764–73.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011;2011(4):CD001333.

    PubMed Central  Google Scholar 

  47. Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M, et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry. 2012;69(9):973–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Ferri M, Minozzi S, Bo A, Amato L. Slow-release oral morphine as maintenance therapy for opioid dependence. Cochrane Database Syst Rev. 2013;(6):CD009879.

    Google Scholar 

  49. Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry. 2007;191(1):55–62.

    Article  PubMed  Google Scholar 

  50. Oviedo-Joekes E, Brissette S, MacDonald S, Guh D, Marchand K, Jutha S, et al. Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder. Drug Alcohol Depend. 2017;176:55–62.

    Article  CAS  PubMed  Google Scholar 

  51. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MCP. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med. 2007;167(22):2469–75.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NHS Borders Addiction Service, Galashiels, Scotland, UK

    James Tidder

  2. University of St Andrews, St Andrews, Scotland, UK

    Alexander M. Baldacchino

  3. NHS Fife Addiction Services, Leven, Scotland, UK

    Alexander M. Baldacchino

  4. Forward Leeds, Leeds, UK

    Joseph Tay Wee Teck

Authors
  1. James Tidder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander M. Baldacchino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph Tay Wee Teck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James Tidder .

Editor information

Editors and Affiliations

  1. Department of Pharmacobiology, Cinvestav, Mexico City, Mexico

    Silvia L. Cruz

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tidder, J., Baldacchino, A.M., Teck, J.T.W. (2022). Medication-Assisted Treatment (MAT) 1: Opioid Substitution Therapy. In: Cruz, S.L. (eds) Opioids. Springer, Cham. https://doi.org/10.1007/978-3-031-09936-6_14

Download citation

Publish with us

Policies and ethics

Search

Navigation